The Cusack lab focuses on cancer treatment resistance mechanisms and has been continuously funded by the NIH since 1997. Cusack is co-inventor of the patent “Use of NF-kappaB inhibition in combination therapy for cancer,” licensed to two pharmaceutical companies and wrote the first clinical trial of combination chemotherapy with the bortezomib (Velcade) for solid organ malignancies, reported in the journal Cancer. Cusack has presented his research nationally and internationally and has published his findings in Nature Medicine, Cancer Research, and Oncogene.
Cusack serves as Chair of the Scientific Program Committee for the Society of Surgical Oncology, member of the Program Committee for the ASCO GI meeting and the ASCO Advanced Clinical Research Awards subcommittee. Cusack also serves on the editorial boards of the Annals of Surgical Oncology, Cancer, and the World Journal of Gastrointestinal Oncology.
Cusack is director of the MGH Division of Surgical Oncology laboratories. Current research projects are evaluating biomarkers of resistance in rectal cancer and Merkel Cell carcinoma and the use of targeted agents against HB-EGF.